CommBio Therapeutics (Shanghai) Co., Ltd. is one of the pioneer biomedical companies focusing on intestinal biology and developing bacterial vector gene therapy in China. Since settled in Zhangjiang Pharma Valley Platform and Johnson & Johnson JLABS@Shanghai in 2019, CommBio has been advancing multiple new drug research projects in the fields of metabolic diseases, oncology and autoimmune diseases.